Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (20)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  2. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428

2022

  1. The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

    Clinical and Translational Oncology, Vol. 24, Núm. 9, pp. 1744-1754

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer

    Oncologist, Vol. 21, Núm. 2, pp. 150-155

2015

  1. Preventive treatments for breast cancer: recent developments

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 257-263

2014

  1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647

2011

  1. Hormone-responsive breast cancer

    Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058

2010

  1. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447

  2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet, Vol. 375, Núm. 9712, pp. 377-384

2009

  1. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314

2008

  1. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2007

  1. Current controversies in the management of early breast cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384

2005

  1. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

    Clinical Cancer Research, Vol. 11, Núm. 24, pp. 8715-8721

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

2003

  1. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy

    Leukemia, Vol. 17, Núm. 2, pp. 437-441

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362